| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
GSK-239512 manufacturers
- GSK-239512
-
- $39.00
-
2026-05-11
- CAS:720691-69-0
- Purity: 99.74%
- Supply Ability: 10g
|
| | GSK-239512 Basic information |
| Product Name: | GSK-239512 | | Synonyms: | GSK-239512;1-(6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy)pyridin-3-yl)pyrrolidin-2-one;GSK-239512 720691-69-0;2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-;GSK-239512, 10 mM in DMSO | | CAS: | 720691-69-0 | | MF: | C23H27N3O2 | | MW: | 377.48 | | EINECS: | | | Product Categories: | | | Mol File: | 720691-69-0.mol |  |
| | GSK-239512 Chemical Properties |
| Boiling point | 607.6±55.0 °C(Predicted) | | density | 1.239±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | form | Solid | | pka | 9.02±0.10(Predicted) | | color | White to light yellow |
| | GSK-239512 Usage And Synthesis |
| Uses | GSK239512 is a potent and brain penetrated H3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD)[1]. | | IC 50 | H3 receptor | | References | [1] Grove RA, et, al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr Alzheimer Res. 2014 Jan;11(1):47-58. DOI:10.2174/1567205010666131212110148 |
| | GSK-239512 Preparation Products And Raw materials |
|